scholarly journals Circulating tumour DNA analysis in multiple myeloma

Oncotarget ◽  
2017 ◽  
Vol 8 (53) ◽  
pp. 90610-90611 ◽  
Author(s):  
Sridurga Mithraprabhu ◽  
Andrew Spencer
Keyword(s):  
Multiple Myeloma ◽  
Dna Analysis ◽  
Circulating Tumour Dna

scholarly journals Circulating Tumour DNA Analysis for Tumour Genome Characterisation and Monitoring Disease Burden in Extramedullary Multiple Myeloma

2018 ◽  
Vol 19 (7) ◽  
pp. 1858 ◽  
Author(s):  
Sridurga Mithraprabhu ◽  
Shreerang Sirdesai ◽  
Maoshan Chen ◽  
Tiffany Khong ◽  
Andrew Spencer
Keyword(s):  
Multiple Myeloma ◽  
Disease Burden ◽  
Dna Analysis ◽  
Circulating Tumour Dna

DNA-repair gene mutations are prevalent in circulating tumour DNA from advanced multiple myeloma patients

2019 ◽  
Vol 19 (10) ◽  
pp. e79-e80
Author(s):  
Andrew Spencer ◽  
Malarmathy Ramachandran ◽  
Kawa choi ◽  
jay hocking ◽  
Daniela Klarica ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Dna Repair ◽  
Gene Mutations ◽  
Repair Gene ◽  
Dna Repair Gene ◽  
Circulating Tumour Dna

scholarly journals Development of circulating tumour DNA analysis for gastrointestinal cancers

ESMO Open ◽  
2020 ◽  
Vol 5 (Suppl 1) ◽  
pp. e000600 ◽  
Author(s):  
Yoshiaki Nakamura ◽  
Kohei Shitara
Keyword(s):  
Dna Analysis ◽  
Residual Disease ◽  
Turnaround Time ◽  
Resistance Mechanisms ◽  
Detection Methods ◽  
Comprehensive Genomic Profiling ◽  
Gi Cancers ◽  
Ctdna Analysis ◽  
Next Generation Sequencing Ngs ◽  
Circulating Tumour Dna

Comprehensive genomic profiling using next-generation sequencing (NGS) enables the identification of multiple genomic biomarkers established in advanced gastrointestinal (GI) cancers. However, tissue-based NGS has limitations, such as long turnaround time and failure to detect tumour heterogeneity. Recently, the analysis of circulating tumour DNA (ctDNA) using polymerase chain reaction-based or NGS-based methods has demonstrated the capability to detect genomic alterations with high accuracy compared with tumour tissue analysis with short turnaround time and identify heterogeneous resistance mechanisms. Furthermore, ctDNA analysis can be repeatedly performed on disease progression to clarify resistant clones. Clinical trials that test the outcome of a selected targeted therapy based on a ctDNA result are ongoing to prospectively evaluate the clinical utility of ctDNA analysis. Furthermore, the improvement of ctDNA analysis beyond current technical limits of mutation-based ctDNA detection methods has expanded the potential for detecting the presence of tumours in patients with no clinically evident disease, such as minimal residual disease and early cancer. Although a careful understanding of the advantages and limitations are required and further prospective studies are needed, the ctDNA analysis has the potential to overcome several challenges in the treatment of various types of cancers at all stages, including GI cancers.

scholarly journals Circulating tumour DNA sequence analysis as an alternative to multiple myeloma bone marrow aspirates

2017 ◽  
Vol 8 (1) ◽  
Author(s):  
Olena Kis ◽  
Rayan Kaedbey ◽  
Signy Chow ◽  
Arnavaz Danesh ◽  
Mark Dowar ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Bone Marrow ◽  
Sequence Analysis ◽  
Dna Sequence ◽  
Dna Sequence Analysis ◽  
Circulating Tumour Dna

Monitoring tumour burden and therapeutic response through analysis of circulating tumour DNA and extracellular RNA in multiple myeloma patients

Leukemia ◽  
2019 ◽  
Vol 33 (8) ◽  
pp. 2022-2033 ◽  
Author(s):  
Sridurga Mithraprabhu ◽  
Rachel Morley ◽  
Tiffany Khong ◽  
Anna Kalff ◽  
Krystal Bergin ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Therapeutic Response ◽  
Tumour Burden ◽  
Extracellular Rna ◽  
Circulating Tumour Dna

P284 DNA analysis by flow cytometry in multiple myeloma. Prognostic value and correlation with clinical parameters

2007 ◽  
Vol 2 (1) ◽  
pp. 218
Author(s):  
D. Malamos ◽  
K. Psarra ◽  
V. Kapsimali ◽  
J. Ekonomidou ◽  
C. Papasteriades
Keyword(s):  
Multiple Myeloma ◽  
Flow Cytometry ◽  
Prognostic Value ◽  
Dna Analysis ◽  
Clinical Parameters

Circulating tumour DNA in multiple myeloma – analysis of the KRAS/NRAS/BRAF mutation in a local cohort

Pathology ◽  
2019 ◽  
Vol 51 ◽  
pp. S127
Author(s):  
Anvita Verma ◽  
Anne-Marie Marivel ◽  
Donna Eng ◽  
Silvia Ling
Keyword(s):  
Multiple Myeloma ◽  
Braf Mutation ◽  
Circulating Tumour Dna
Sign in / Sign up

Export Citation Format

Share Document